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Abstract
Background: The forced vital capacity (FVC) test is routinely performed to evaluate pulmonary function in patients with chronic obstructive 
pulmonary disease (COPD). However, the influence of the FVC maneuver on the cardiovascular system of patients with COPD is poorly 
understood. Objectives: To analyze the behavior of heart rate (HR), blood pressure (BP) and heart rate variability (HRV) during the FVC 
test in COPD patients. Methods: Nineteen men with COPD (72±7 years, GOLD stage I=3, II=5, III=7 and IV=4 patients) performed 
the FVC test while having their HR monitored. HRV was assessed in time (rMSSD) and frequency domains (LF, HF and LF/HF) at rest, 
before and after the best FVC maneuver. BP was measured at rest, immediately before and at the end of the test, as well as 10 minutes 
after the end of the test. Results: At the beginning of the FVC maneuver, HR decreased (p<0.001) and then increased gradually until 
the end of the test (p<0.001). After the end of maneuver, HR continued to increase until it reached a peak (p<0.001), and then it fell 
quickly to below at-rest values (p<0.001) prior to returning to baseline. The BP and HRV indices did not change during the assessment. 
Conclusion: The FVC test influences the behavior of COPD patient HR without changing autonomic control or BP.
Keywords: chronic obstructive pulmonary disease; spirometry; vital capacity; heart rate; autonomic nervous system.
Resumo
Contextualização: O teste de capacidade vital forçada (CVF) é rotineiramente realizado na avaliação da função pulmonar de pacientes 
com doença pulmonar obstrutiva crônica (DPOC). Entretanto, permanece pouco compreendida a influência do teste de CVF sobre o 
sistema cardiovascular de pacientes com DPOC. Objetivos: Analisar o comportamento da frequência cardíaca (FC), pressão arterial 
(PA) e variabilidade da frequência cardíaca (VFC) no teste de CVF na DPOC. Métodos: Dezenove homens com DPOC (72 ± 7 anos, 
no estágio de gravidade GOLD I=3, II=5, III=7 e IV=4 pacientes) realizaram a manobra de CVF e tiveram sua FC monitorada durante 
todo o exame, e a VFC analisada nos domínios do tempo (rMSSD) e da frequência (BF, AF e BF/AF) durante o repouso, antes e após 
a melhor manobra de CVF. A PA foi analisada no repouso, imediatamente ao final da manobra de CVF e 10 minutos após o término de 
todos os testes. Resultados: Ao início da manobra de CVF, a FC reduziu (p<0,001) e, em seguida, aumentou progressivamente até o 
final do teste (p<0,001). Após término da manobra, a FC continuou a aumentar até atingir um pico (p<0,001) e depois caiu rapidamente 
a valores inferiores aos de repouso (p<0,001) e retornou ao seu valor basal. A PA e os índices da VFC não sofreram alterações nos 
períodos analisados. Conclusão: O teste de CVF influencia o comportamento da FC, sem alterar o seu controle autonômico, bem como 
a PA em pacientes com DPOC nos períodos analisados.
Palavras-chave: doença pulmonar obstrutiva crônica; espirometria; capacidade vital; frequência cardíaca; sistema nervoso autônomo.
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Introduction 
Chronic obstructive pulmonary disease (COPD) is linked 
with high mortality and morbidity, is progressive and irrevers-
ible, and is characterized by obstruction of airflow1. Besides 
pulmonary involvement, cardiovascular events are commonly 
observed in this population2, although the mechanisms re-
sponsible for these manifestations have not yet been fully 
elucidated. It is postulated that chronic systemic inflamma-
tion and/or cardiovascular autonomic neuropathy may be 
involved3-6, since there is evidence that COPD patients present 
dysautonomia, sympathetic hyperactivity, reduced vagal tone 
and heart rate variability (HRV). These phenomena are highly 
associated with the appearance of arrhythmias and a risk of 
sudden death in this population7-13.
An important method for diagnosing, classifying and following 
the progression of COPD is spirometry1,14, which is considered the 
best means of assessing pulmonary function15-17 and is routinely 
performed via the forced vital capacity (FVC) maneuver18,19.
It is known that respiratory patterns exert great influ-
ence on the cardiovascular system20,21 and that intrathoracic 
pressure, right atrium variations, changes in autonomic 
modulation and displacement of thoracic organs occur 
during forced expiratory maneuvers, which can induce the 
appearance of cardiac arrhythmias5,22. Much of the influ-
ence of breathing on the cardiovascular system occurs due 
to complex interaction with autonomic modulation of the 
cardiorespiratory system, which is generated by the close 
relationship between central neural control of these sys-
tems, the modulation of baroreceptors and chemoreceptors, 
changes in venous return and blood pressure (BP), and the 
activation of pulmonary and thoracic stretch receptors23.
Due to cardiovascular involvement, the greater suscepti-
bility of COPD patients to arrhythmic events, the significant 
influence of respiratory pattern on the cardiovascular system 
and the importance of spirometry in the clinical routine of 
these patients, the hypothesis was raised that the performance 
of forced respiratory maneuvers such as the FVC test influ-
ences cardiovascular system and autonomic cardiac control 
variables in this population. Thus, the aim of this study was to 
analyze heart rate (HR), blood pressure and heart rate variabil-
ity in COPD patients undergoing FVC testing.
Methods 
Study design 
Cross-sectional observational study.
Subjects
A sample of 29 male patients with a clinical diagnosis of 
COPD who were undergoing treatment at the Center for Re-
search and Care in Physical Therapy and Rehabilitation of the 
Universidade Estadual Paulista “Júlio Mesquita Filho” (UNESP), 
Presidente Prudente, SP, Brazil were selected. 
The inclusion criteria were: COPD, a body mass index 
(BMI)<30 kg/m2, the use of no medicine that might influence 
autonomic activity, no infections or inflammations of any 
kind, no metabolic disease or cardiopulmonary disorder that 
might interfere in cardiac autonomic control, and the abil-
ity to perform spirometry according to American Thoracic 
Society (ATS) criteria for acceptability and reproducibility24. 
Patients were required to have undergone outpatient medical 
treatment for at least the previous six months, to have been 
clinically stable for at least the previous 30 days and to have 
been using appropriate medication.
All procedures used in this study were approved by the Re-
search Ethics Committee of the Faculdade de Ciências e Tec-
nologia (FCT), UNESP, Presidente Prudente, SP, Brazil (protocol 
nº 014/2005) and were in accordance with resolution 196/96 of 
The Ministry of Health. All volunteers were properly informed 
about the procedures and objectives of this study and, after 
having agreed, signed an informed consent form.
Method
In order to reduce the subjects’ anxiety level during data 
collection sessions, the equipment was prepared and the en-
vironmental conditions controlled prior to their arrival, with 
a minimum of personnel circulating in the laboratory. All tests 
were carried out in the morning in order to avoid circadian 
influence, with the temperature maintained between 20 and 
25ºC and the humidity between 50 and 60%. 
Patients were instructed to avoid alcoholic beverages and 
stimulants such as coffee and tea, and to have had a light 
breakfast 2 hours before performing the protocol. Those who 
used maintenance medication (bronchodilators, mucolytics, 
anti-inflammatories, etc.) were also instructed to interrupt 
their use 12 hours before beginning the protocol.
On the assessment day, the volunteers met the research-
ers, were familiarized with the materials and were instructed 
again about the procedures to be performed. Anthropomet-
ric measurements were obtained following the methods of 
Lohman, Roche and Martorell25. Weight was measured on a 
digital balance (Plenna TIN 00139 MAXIM, São Paulo, Bra-
zil) and height was measured with a stadiometer (ES 2020 
- Sanny, São Paulo, Brazil). BMI was calculated according to 
the following formula: weight (kg)/height (m)2.
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Next, the transmitter belt was positioned over the patients’ 
precordium region, and a Polar S810i heart rate receiver (Polar 
Electro, Kempele, Finland) was attached to the wrist. The patients 
then remained seated for 15 minutes in absolute rest, after which 
the FVC test was carried out. Between each test maneuver, the 
patients rested for at least 5 minutes after their HR had returned 
to baseline in order to stabilize it for the variability analysis.
Evaluation protocol
Spirometry
The FVC test was performed with a spirometer (MIR - Spi-
robank version 3.6, Rome, Italy) according to criteria estab-
lished by the ATS24, with predictive values based on Knudson 
et al.26. During the test, the volunteers were seated at 90º of hip 
flexion without posterior trunk support and with their arms 
relaxed and upright. Patients were instructed to perform two 
complete respiratory cycles at tidal volume followed by a deep 
inspiration until reaching total pulmonary capacity and then 
by an abrupt and continuous expiration until reaching residual 
volume. The test was carried out with a minimum of three and 
a maximum of eight repetitions.
Monitoring the cardiovascular system
Only the best curve of the pulmonary function test, which 
was chosen by the highest FVC value obtained among the 
reproducible curves, was used to analyze the behavior of the 
HR and HRV indices.
HR behavior was registered beat-by-beat during the entire 
experimental protocol with the Polar S810i frequency meter 
(Polar Electro, Kempele, Finland), which has been previously 
validated for capturing data for HRV analysis27,28. Data were col-
lected at a sampling frequency of 1000 Hz and transferred to a 
computer through the Polar® interface via infrared signal. The 
QRS detection timing accuracy of the Polar® interface was set 
at 1 ms29. Data was recorded with Polar Precision Performance 
3.0 software and displayed in a tachogram. The program identi-
fies the QRS complexes, and the resulting signal is processed 
through a standard filter in the above-described equipment30. 
The RR intervals were manually edited, and areas with ectopic 
beats and artifacts were removed.
HRV analysis was performed on the following sections: a) 
the final 300s of the initial rest; b) 300s before the beginning of 
the best FVC test; and c) 300s after the return of HR to baseline 
value after the best FVC test. Only temporal series of more than 
256 RR intervals were used for analysis31.
The RR intervals were exported for analysis by HRV Analy-
sis Software (Biosignal Analysis and Medical Imaging Group, 
University of Kuopio, Finland)32,33. With this program, HRV 
calculation was performed in the temporal and frequency 
domains. In the temporal domain, the rMSSD index was evalu-
ated, which corresponds to the square root of the mean sum of 
the squared differences between  adjacent normal RR intervals, 
registered in an time interval, divided by the number of RR in-
tervals minus one, expressed in ms34.
In the frequency domain, Fast Fourier transform (FFT) spec-
tral analysis, a non-parametric method, was used. The spectral 
power was determined according to the Task Force of the Euro-
pean Society of Cardiology and the North American Society of 
Pacing Electrophysiology31 as follows: a) high frequency (HF) was 
estimated between 0.15 and 0.40 Hz, b) low frequency (LF) was 
estimated between 0.04 and 0.15 Hz, and c) very low frequency 
(VLF) was estimated between 0.003 and 0.04 Hz. The LF/HF ra-
tio was considered as a marker of sympatho-vagal balance35. The 
HF and BF values were given in absolute units (ms2) and nor-
malized units (un). The normalized unit was calculated as: HF or 
LF / (total spectral power - VLF) × 100.
BP was measured indirectly with an aneroid sphygmoma-
nometer (Welch Allyn - Tycos, New York, USA) and a stetho-
scope (Littmann, Saint Paul, USA) immediately after the initial 
rest and 10 minutes after the completion of all FVC tests.
Statistical analysis
Data are expressed as mean and standard deviation. Nor-
mality was verified by the Kolmogorov-Smirnov test. Analysis 
of variance (ANOVA) for repeated measures with post-hoc 
Student-Newman-Keuls was used to compare data. The signifi-
cance level was set at 5% for all tests. The program Sigma Stat 
3.5 (SPSS Inc, USA) was used for statistical analysis.
The study power was calculated according to the number 
of analyzed volunteers and with a significance level of 5% (two 
tailed), thus guaranteeing a test power greater than 80% for 
detecting differences between variables.
Results 
Of the 29 eligible patients, ten did not meet the inclusion cri-
teria. With respect to the analyzed patients’ comorbidities, two 
had a history of gout and two of sinusitis or typhoid fever. The 
anthropometric characteristics and pulmonary function of the 
19 patients who concluded the study are expressed in Table 1.
To analyze the behavior of the cardiovascular system, the 
best FVC test was chosen because the comparison of HR and 
HRV index values revealed no differences between them, re-
gardless of the number of tests performed (ANOVA, p≥0.05).
The predominant HR behavior during the FVC tests was 
initially a decrease (79%), followed by a progressive increase 
with oscillations (95%), and the highest value was reached after 
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Even after the end of the FVC test, HR continued to increase an av-
erage of 21.3±13.9 bpm (75.9±14.6 vs. 97.2±21.8; p<0.001) and then 
reduce an average of 4.9±7.6 bpm (75.9±14.6 vs. 71.0±11.2, p <0.001) 
compared to resting values. The HR peak reached after the end of 
the FVC test was an average 9.5±8.3 bpm higher than obtained at 
the end of the test (87.7±16.8 vs. 97.2±21.8; p<0.001 ).
Despite an average increase of 6.3±20.1 mmHg (136.8±21.4 
vs. 143.16±30.0) in systolic BP from the beginning to the end 
of the test and upon returning to baseline value after 10 min-
utes of rest (133.2±23.8 mmHg), there were no differences 
between the analyzed periods (p≥0.05). Diastolic BP remained 
unchanged during the periods analyzed (83.2±12.9 mmHg vs 
85.3±13.9 mmHg vs 83.2±13.8 mmHg; p≥0.05).
The values of HRV indices can be observed in Table 3. There 
were no statistically significant differences in HRV indices in 
the temporal (rMSSD) or the frequency (LF, HF, and LF / HF 
ratio) domains between the analyzed periods (p≥0.05).
Discussion 
The results of this study showed that the FVC test produced 
significant changes in COPD patient HR but did not change the 
BP or HRV index values during the analyzed periods.
The HR response to the FVC test was characterized by a 
reduction at the beginning of the inspiratory phase and by an 
increase at its end, with the HR peak being reached after the 
end of the test. The HR then decreased below resting HR values 
and subsequently returned to baseline value.
The initial reduction and subsequent increase in HR, 
which were observed in this study during the execution of the 
inspiratory phase of the FVC test, were similar to the pattern 
observed by Martins et al.36 during the sustained inspiratory 
breath-holding maneuver.
It is postulated that the initial decrease in HR during the 
inspiratory phase of the test may be related, at least in part, 
to the activation of bronchopulmonary C-fibers. These fibers, 
when stimulated, produce reflex bradycardia and hypotension 
and may be related to the observed reduction in HR37-39.
The subsequent progressive increase in HR may be at-
tributed to the decrease in intrathoracic pressure that, con-
sequently, produces a reduction in both the stroke volume of 
Figure 1. Example of heart rate (HR) behavior during FVC test in a 
COPD patient. 
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Table 1. Anthropometric characterization, pulmonary function and 
severity of 19 patients with COPD.
Data are expressed as mean ± standard deviation. BMI=body mass index; kg=kilogram; 
cm=centimeter; GOLD=Global Initiative for Obstructive Lung Disease; I=mild; 
II=moderate; III=severe; IV=very severe; FEV1=forced expiratory volume in one second; 
FVC=forced vital capacity.
Anthropometric data
Age (years) 72±8
Weight (kg) 62.4±15.4
Height (cm) 164.3±5.3
BMI (kg/m2) 22.9±5.2
GOLD stage
I / II / III / IV 3 / 5 / 7 / 4
Pulmonary Function
FEV1 (% of predicted value) 53.1±29.2
FVC (% of predicted value) 100.3±34.5
FEV1/FVC 40.8±11.2
Table 2. Values of heart rate delta obtained during the FVC maneuver in relation to initial heart rate.
SD=standard deviation; CI95=confidence interval of 95%; HRI=initial heart rate (HR); HRQI=initial HR decrease in FVC test; HRF=HR at the end of the FVC test; HRP=the highest HR value 
reached after finishing the FVC test; HRQF=HR decreased after the end of the FVC test.
∆HRQI - HRI ∆HRF - HRI ∆HRP - HRI ∆HRQF - HRI
Mean±SD -6.10±8.5 11.8±10.9 21.3±13.9 -4.9±7.6
Median -2 10 17 -2
[CI95] [-10.2 – -1.9] [6.5 – 17.0] [14.6 – 27.9] [-8.6 – -1.2]
[Minimum – Maximum] [-32 – 0] [-10 – 38] [3 – 60] [-27 – 0]
the end of the maneuver (84%). The HR then decreased below 
the initial resting HR (58%) and later returned to baseline. One 
example of this behavior can be observed in Figure 1.
Table 2 shows the delta HR values obtained during the FVC 
maneuver in relation to initial HR. It was observed that at the be-
ginning of the inspiratory phase of the FVC test, HR was reduced 
an average of 6.10±8.5 bpm (75.9±14.6 vs. 69.8±10.0 p<0.001) and 
then increased an average of 11.8±10.9 bpm until the end of the test, 
compared to the resting values (75.9±14.6 vs. 87.7±16.8; p<0.001). 
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the left ventricle and in BP. This, in turn, would produce an 
increase in HR mediated by the activation of baroreceptors40. 
Another aspect to be considered is the stimulation of pulmo-
nary stretch receptors induced by an increase in tidal volume 
during inspiration41, which produces cardiac acceleration with 
subsequent tachycardia38.
During the expiratory phase of the FVC test, the HR contin-
ued to increase gradually, which may be related to an increase 
in intrathoracic pressure and a decrease in venous return 
which, in turn, promotes changes in myocardial contractility, 
vasomotor tone and baroreflex control42-44. The reduction of 
vagal activity followed by the increase in sympathetic activity 
that occurs during expiration can also increase HR42.
After the end of the FVC test, the HR continued to increase 
until it reached its highest value, which can be explained by the 
release of the expiratory effort43,44. During a sudden decrease 
in intrathoracic pressure, a large amount of blood is seques-
tered to the pulmonary vascular bed, which reduces the left 
ventricular filling and causes a rise in HR44. Moreover, the lower 
conduction velocity and the slow uptake and neutralization of 
noradrenaline by the sympathetic nervous system causes a 
gradual decay in the stimulus for increased HR, even after ces-
sation of the expiratory effort45.
The decrease in HR after the accomplishment of the FVC 
maneuver is similar to that observed by Marães et al.43 after 
the release of strain during the Valsalva maneuver (phase 
IV), which they attributed to increased reflex vagal activity 
and inhibited sympathetic activity due to great stimulation 
of baroreceptors during the expiratory phase and which was 
followed by vasodilation and a reduction in HR to below base-
line values43.
Despite the influence of FVC maneuvers on HR fluctuations, 
the analysis of HRV indices showed no significant changes in 
the analyzed periods. This is similar to the results of Marães et 
al.43, who analyzed HRV before and after the Valsalva maneu-
ver in middle-aged individuals and observed no changes in the 
rMSSD index. The lack of change in HRV indices may be related 
to the short duration of the maneuver, the advanced age of the 
volunteers or the probable autonomic dysfunction present in 
these individuals. Paschoal, Petrelluzzi and Gonçalves13 and 
Acharya et al.46 observed that advancing age may reduce heart 
rate variability. Other studies have verified that COPD patients 
have depressed HRV when compared to healthy subjects 
matched by age and sex7,8,47-49.
Furthermore, the FVC maneuver did not modify BP be-
havior during the analyzed periods. However, it should be 
pointed out that an indirect (auscultatory) method was used 
to measure BP, which, although reliable, did not allow measure-
ment during the entire period of FVC performance, but only 
before and after the maneuver. Therefore, the possibility that 
the test promoted changes in this variable during its execution 
should not be discarded.
The results of this study may benefit health professionals 
in the clinical setting, particularly physiotherapists, since 
according to COFFITO SECEX communication 123/9650 
they are sufficiently qualified and specialized to perform 
spirometry.
Spirometry is considered the gold standard for diagnos-
ing and evaluating COPD because it is the most reproducible, 
standardized and objective way of measuring airflow limita-
tion1. Thus, understanding cardiovascular system responses 
to the FVC test, performed by spirometry, provides physical 
therapists with a better means of monitoring COPD patients 
during its performance.
A limitation of this study was the lack of a healthy control 
group, which might have clarified if the results were due solely 
to the FVC test or were influenced by the disease. Additionally, 
the inclusion of patients whose COPD severity varied widely 
could be considered another limiting factor, although most of 
our patients (63%) were classified according to GOLD as stage 
II and III. Some studies have indicated an association between 
low FEV1 and a high risk of cardiovascular disease51,52, although 
Camillo et al.53 observed no association between the degree of 
bronchial obstruction and the values of HRV indices. 
Another aspect to be considered is the way that HR pro-
cesses are analyzed during FVC. During the maneuver, the 
time necessary for completing the inspiratory and expiratory 
movements varies between subjects, which complicates the 
analysis of HR response over time, and thus it was decided only 
to describe what happened to it during the maneuver.
This study represents a description of cardiovascular sys-
tem responses while performing the FVC maneuver, and the 
methodology allowed inferences to be made about the mecha-
nisms involved in these responses. However, more studies in-
vestigating these mechanisms should be carried out.
Table 3. HRV indices of COPD patients at rest, before and after the 
FVC maneuver.
rMSSD=square root of the mean of the squared differences between adjacent normal RR 
intervals recorded in a time interval, divided by the number of RR intervals minus one; 
HF=high frequency; LF=low frequency; nu=normalized unit; ms=milliseconds. (Repeated 
measures ANOVA with post-hoc Student-Newman-Keuls; p>0.05).
Rest Before FVC After FVC
Time domain
rMSSD (ms) 17.6±11.3 22.5±18.5 23.4±30.4
Frequency domain
LF (ms2) 116.9±116.5 158.3±204.2 157.6±225.2
nu 72.3±14.9 66.9±16.4 70.8±13.7
HF (ms2) 52.9±67.9 95.5±186.0 92.3±239.4
nu 27.7±14.9 33.1±16.4 29.2±13.7
LF/HF 4.0±3.4 3.6±4.3 3.6±3.2
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The present results suggest that the FVC test significantly 
influences the HR behavior of COPD patients, but did not 
change autonomic modulation, according to HRV indices, or 
BP during the studied periods.
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